Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M. Yamamoto T, et al. Among authors: damdinsuren b. Clin Cancer Res. 2004 Dec 1;10(23):7884-95. doi: 10.1158/1078-0432.CCR-04-0794. Clin Cancer Res. 2004. PMID: 15585621
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Ota H, et al. Among authors: damdinsuren b. Br J Cancer. 2005 Sep 5;93(5):557-64. doi: 10.1038/sj.bjc.6602742. Br J Cancer. 2005. PMID: 16106266 Free PMC article.
[A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].
Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Yoshioka S, Kato H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Nakamura M, et al. Among authors: damdinsuren b. Gan To Kagaku Ryoho. 2005 Oct;32(11):1824-8. Gan To Kagaku Ryoho. 2005. PMID: 16315953 Japanese.
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M. Wada H, et al. Among authors: damdinsuren b. Liver Int. 2006 May;26(4):414-23. doi: 10.1111/j.1478-3231.2006.01243.x. Liver Int. 2006. PMID: 16629644
Vitamin K2 has growth inhibition effect against hepatocellular carcinoma cell lines but does not enhance anti-tumor effect of combination treatment of interferon-alpha and fluorouracil in vitro.
Nakamura M, Nagano H, Noda T, Wada H, Ota H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Doki Y, Umeshita K, Dono K, Sakon M, Monden M. Nakamura M, et al. Among authors: damdinsuren b. Hepatol Res. 2006 Aug;35(4):289-95. doi: 10.1016/j.hepres.2006.04.014. Epub 2006 Jun 12. Hepatol Res. 2006. PMID: 16769246
Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Nakamura M, et al. Among authors: damdinsuren b. J Hepatol. 2007 Jan;46(1):77-88. doi: 10.1016/j.jhep.2006.07.032. Epub 2006 Sep 25. J Hepatol. 2007. PMID: 17045692
46 results